Evidence Hub

AB0100 to study the T cell and cytokine profile in ankylosing spondylitis with effects of tacrolimus and tadalafil on the cytokines in-vitro

P. Mehta, K. Singh, M. K. Rai, D. Misra, V. Agarwal

Annals of the Rheumatic Diseases, 2023

23 participants

Abstract

Most studies have shown mixed results of Interleukin (IL)17 and IL-23 levels in patients with Ankylosing Spondylitis (AS) compared to controls; with animal studies showing a good correlation between activation of IL 23-IL 27 pathway and radiologic progression. Targeting this pathway in humans has yielded benefits with reduced inflammation and radiologic progression in AS. Controlling inflammation and fibrosis is the key to prevent osteoproliferation. Tacrolimus and tadalafil have shown to inhibit the Th17 pathway and profibrotic pathways respectively.To study the T cell (Th17, PD1, CD25+ CD4 T cells) and cytokine profile (IL-17, IL-23, TGF- β) in AS with influence of disease duration and activity on the above profile. To also study the effect of tacrolimus and tadalafil in ex-vivo peripheral blood monocyte (PBMC) cultures to study their anti-inflammatory and anti-fibrotic potential.Patients with AS (ASAS classification criteria) without peripheral disease and not on biologic therapy were recruited and their demographic, clinical profile, disease activity and radiologic indices were recorded. Age and sex matched healthy controls (HC, n=21) were also recruited. Peripheral blood was drawn and sera stored; PBMCs were isolated and cultured. Serum and PBMC culture supernatant (CS) were measured for IL-17, IL-23 and TGF-β. These cytokines were measured at baseline, after stimulation with anti-CD3CD28 antibodies, and after treatment with tacrolimus(10mM/ml), tadalafil(10mM/ml) and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free